Pharmaceutical-embodied technical progress, longevity and quality of life: drugs as 'equipment for your health.'

Article Abstract:

The impacts of technical progress in pharmaceutical industry, in terms of new drugs, on quality of life and improving health conditions are investigated. Findings show that people who consumed newer medicines experienced better health conditions after treatment and had fewer limitations than those who consulmed older drugs. The role of techn ical progress in drugs, as compared to that in equipment, in increasing economic equality and growth is analyzed.

United States, Product development, Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Drugs, Metabolic Agents NEC, Metabolic Agents, Usage, Economic aspects, Report

---

Commentary

Article Abstract:

A paper on regulation, competition and differentiation of various statins is reviewed. Economists were fount to be more concerned about generic competition instead of therapeutic competition. Recommendations for future research are supplied.

Europe, Legal issues & crime, Government regulation (cont), Marketing procedures, Government regulation, Commodity & service prices, Legal/Government Regulation, Laws, regulations and rules, Prices and rates, Marketing, Criticism and interpretation, Company marketing practices, Company pricing policy, Statins, Critical essay

---

Similar abstracts:

• Abstracts: Aggregate returns to scale embodied technology change: theory and measurement using stock market data
• Abstracts: The most technologically progressive decade of the century. Inequality, lobbying, and resource allocation. Mortality reductions, educational attainment, and fertility choice
• Abstracts: Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion. Benefits and costs of newer drugs: an update
• Abstracts: The cost of biopharmaceutical R&D: is biotech different? Commentary. Generic competition and market exclusivity periods
• Abstracts: Commentary. Commentary: drug and vaccine pricing and innovation, what is the story?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.